Furthermore, recent studies have identified multiple additional pathways through which ARNT may contribute to tumor initiation, progression, and drug resistance, including the fibronectin/integrin β1/FAK, Myc/Miz/CDKN2B, NF-κB, p38α-MAPK, and canonical AHR/ARNT signaling pathways [59,60,61,62]. This evidence concerns the gene CDKN2B and neoplasm.